PL3802517T3 - Alkoksy-podstawione pochodne pirydynylu jako antagoniści receptora lpa1 i ich zastosowanie w leczeniu zwłóknienia - Google Patents

Alkoksy-podstawione pochodne pirydynylu jako antagoniści receptora lpa1 i ich zastosowanie w leczeniu zwłóknienia

Info

Publication number
PL3802517T3
PL3802517T3 PL19731163.2T PL19731163T PL3802517T3 PL 3802517 T3 PL3802517 T3 PL 3802517T3 PL 19731163 T PL19731163 T PL 19731163T PL 3802517 T3 PL3802517 T3 PL 3802517T3
Authority
PL
Poland
Prior art keywords
fibrosis
alkoxy
treatment
receptor antagonists
substituted pyridinyl
Prior art date
Application number
PL19731163.2T
Other languages
English (en)
Polish (pl)
Inventor
Martin Bolli
Christine Brotschi
Cyrille Lescop
Jodi T. Williams
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of PL3802517T3 publication Critical patent/PL3802517T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PL19731163.2T 2018-06-07 2019-06-05 Alkoksy-podstawione pochodne pirydynylu jako antagoniści receptora lpa1 i ich zastosowanie w leczeniu zwłóknienia PL3802517T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2018065016 2018-06-07
PCT/EP2019/064690 WO2019234115A1 (en) 2018-06-07 2019-06-05 Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis

Publications (1)

Publication Number Publication Date
PL3802517T3 true PL3802517T3 (pl) 2023-05-22

Family

ID=66912779

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19731163.2T PL3802517T3 (pl) 2018-06-07 2019-06-05 Alkoksy-podstawione pochodne pirydynylu jako antagoniści receptora lpa1 i ich zastosowanie w leczeniu zwłóknienia

Country Status (22)

Country Link
US (1) US12344597B2 (https=)
EP (1) EP3802517B1 (https=)
JP (1) JP7386183B2 (https=)
KR (1) KR102826034B1 (https=)
CN (1) CN112236424B (https=)
AU (1) AU2019282274A1 (https=)
BR (1) BR112020024879A2 (https=)
CA (1) CA3102683A1 (https=)
DK (1) DK3802517T3 (https=)
EA (1) EA202092955A1 (https=)
ES (1) ES2940695T3 (https=)
FI (1) FI3802517T3 (https=)
HR (1) HRP20230243T1 (https=)
HU (1) HUE061559T2 (https=)
LT (1) LT3802517T (https=)
MX (1) MX2020013291A (https=)
PL (1) PL3802517T3 (https=)
PT (1) PT3802517T (https=)
RS (1) RS63990B1 (https=)
SI (1) SI3802517T1 (https=)
TW (1) TW202016090A (https=)
WO (1) WO2019234115A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119162A1 (es) * 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
KR20220109439A (ko) 2019-12-04 2022-08-04 이도르시아 파마슈티컬스 리미티드 섬유증 질환의 치료에서 사용하기 위한 아제티딘 lpa1 수용체 길항제와 피르페니돈 및/또는 닌테다닙의 조합
FI20225388A1 (en) 2022-05-05 2023-11-06 Equinorm Ltd New heterocyclic compounds, preparation methods and their uses
WO2025169931A1 (ja) * 2024-02-05 2025-08-14 Ube株式会社 カルボキサミド化合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130088C (https=) 1960-03-14
GB9420763D0 (en) 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
WO2001032173A1 (en) 1999-10-29 2001-05-10 Yamanouchi Pharmaceutical Co., Ltd. Kainic acid neurocytotoxicity inhibitors
AU2001262185A1 (en) 2000-04-10 2001-10-23 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
WO2002062389A1 (en) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US7435824B2 (en) 2002-04-19 2008-10-14 Bristol-Myers Squibb Company Prodrugs of potassium channel inhibitors
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
JP4847868B2 (ja) 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
EP1679069A4 (en) 2003-10-21 2009-05-13 Dainippon Sumitomo Pharma Co NEW PIPERIDINE DERIVATIVE
EP1687296A1 (en) 2003-11-18 2006-08-09 Warner-Lambert Company LLC Antibacterial aminoquinazolidinedione derivatives
WO2006091862A2 (en) 2005-02-24 2006-08-31 Kemia, Inc. Cytokine inhibitors and their use in therapy
HRP20130719T1 (en) 2005-08-24 2013-09-30 Eisai R&D Management Co., Ltd. Novel pyridine derivative and pyrimidine derivative (3)
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
CA2691214A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
JP5164510B2 (ja) 2006-10-06 2013-03-21 日本曹達株式会社 含窒素複素環化合物および有害生物防除剤
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
ATE552257T1 (de) 2007-10-18 2012-04-15 Merck Sharp & Dohme Positive allosterische chinolizidinon-m1- rezeptormodulatoren
US8193202B2 (en) 2008-04-21 2012-06-05 Lexicon Pharmaceuticals, Inc. LIMK2 inhibitors, compositions comprising them, and methods of their use
RU2529484C2 (ru) 2008-05-05 2014-09-27 Санофи-Авентис Ациламино-замещенные производные конденсированных циклопентанкарбоновых кислот и их применение в качестве фармацевтических средств
MX2011001938A (es) 2008-08-26 2011-03-29 Boehringer Ingelheim Int Tienopirimidinas para composiciones farmaceuticas.
BR112012006686B8 (pt) * 2009-09-25 2021-05-25 Astellas Pharma Inc compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa
CN103270036B (zh) 2010-08-05 2015-11-25 佐蒂斯有限责任公司 作为抗寄生物剂的异噁唑啉衍生物
TW201305178A (zh) 2010-10-29 2013-02-01 Glenmark Pharmaceuticals Sa 作為mPGES-1抑制物的三環化合物
EP3360552A1 (en) 2010-12-07 2018-08-15 Amira Pharmaceuticals, Inc. Polycyclic lpa1 antagonist and uses thereof
US9073895B2 (en) 2010-12-16 2015-07-07 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
ME02412B (me) 2011-03-10 2016-09-20 Zoetis Services Llc Spirociklični derivati izoksazolina kao antiparazitska sredstva
JP2015506349A (ja) 2011-12-21 2015-03-02 アルデリックス, インコーポレイテッド 非全身性tgr5アゴニスト
US20140148484A1 (en) 2012-11-23 2014-05-29 Boehringer Ingelheim International Gmbh Pyrazole compounds for treating hairloss
TW201444820A (zh) * 2013-03-13 2014-12-01 Abbvie Inc 吡啶cdk9激酶抑制劑
AR108185A1 (es) 2016-04-06 2018-07-25 Abbvie Inc Amidas terciarias y método para su uso
AR119162A1 (es) 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
KR20220109439A (ko) 2019-12-04 2022-08-04 이도르시아 파마슈티컬스 리미티드 섬유증 질환의 치료에서 사용하기 위한 아제티딘 lpa1 수용체 길항제와 피르페니돈 및/또는 닌테다닙의 조합

Also Published As

Publication number Publication date
EA202092955A1 (ru) 2021-04-08
BR112020024879A2 (pt) 2021-03-09
JP7386183B2 (ja) 2023-11-24
US12344597B2 (en) 2025-07-01
US20210246116A1 (en) 2021-08-12
RS63990B1 (sr) 2023-03-31
SI3802517T1 (sl) 2023-04-28
JP2021527046A (ja) 2021-10-11
HRP20230243T1 (hr) 2023-04-14
ES2940695T3 (es) 2023-05-10
MX2020013291A (es) 2021-04-29
KR102826034B1 (ko) 2025-06-27
CA3102683A1 (en) 2019-12-12
DK3802517T3 (da) 2023-03-13
EP3802517B1 (en) 2022-12-21
KR20210018900A (ko) 2021-02-18
HUE061559T2 (hu) 2023-07-28
CN112236424A (zh) 2021-01-15
WO2019234115A1 (en) 2019-12-12
TW202016090A (zh) 2020-05-01
FI3802517T3 (fi) 2023-03-23
AU2019282274A1 (en) 2021-01-28
LT3802517T (lt) 2023-03-10
CN112236424B (zh) 2024-03-15
EP3802517A1 (en) 2021-04-14
PT3802517T (pt) 2023-03-20

Similar Documents

Publication Publication Date Title
SG11202106144VA (en) Compositions for the delivery of therapeutic agents and methods of use and making thereof
LT3675854T (lt) Piperidinilindolo dariniai, skirti c3 glomerulopatijai gydyti
IL272016A (en) Pyrrolidine history and their use as TLR7/8 antagonists
IL277694A (en) Pharmacologically active history of pyrazolo-trizine and/or pyrazolo-pyrimidine
SI3802517T1 (sl) Alkoksi-substituirani piridinilni derivati kot antagonisti receptorja LPA1 in njihova uporaba pri zdravljenju fibroze
IL280479A (en) TLR7/8 antagonists and their use
SI4076652T1 (sl) Farmacevtsko sprejemljiva sol atrazentana za uporabo v zdravljenju iga nefropatije
PL3615035T3 (pl) Zastosowanie 20-hydroksyekdyzonu i jego pochodnych w leczeniu miopatii
SI4014976T1 (sl) Aprocitentan za uporabo pri zdravljenju hipertenzije in sorodnih bolezni v kombinaciji z valsartanom
IL289164A (en) The history of imidazo[2,1-a)pyridinyl and their use in the treatment of diseases
EP3215509A4 (en) Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
IL285025A (en) History of heterocyclic carboxamides, their preparation and use
EP3215510A4 (en) Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
IL266128B (en) History of naphthyridinone and its use in the treatment of arrhythmia
IL281100A (en) Methods of modulating m2 macrophage polarization and use of same in therapy
SG11202010985TA (en) Heterocyclic derivatives and use thereof
ZA201903828B (en) Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases
IL282526A (en) 5-Azaindazole history and their use
IL282527A (en) 5-Azaindazole history and their use
PT3215143T (pt) Combinação compreendendo espirulina e palmitoíletanolamida
IL277805A (en) Use of gaboksadol in the treatment of substance use disorders
HUE050456T2 (hu) Dimetil-amino-mikeliolid tüdõfibrózis kezelésében történõ alkalmazásra
IL274868A (en) History of imidazopyridine and their use as medicine
EP3648789C0 (en) MTMR2-S POLYPEPTIDE FOR USE IN THE TREATMENT OF MYOPATHY
EP3579825A4 (en) SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND USES THEREOF AS MEDICINES FOR TREATMENT OF LIVER FIBROSIS